-
公开(公告)号:US08785462B2
公开(公告)日:2014-07-22
申请号:US13503340
申请日:2010-10-20
申请人: Takeshi Kuribayashi , Hideki Kubota , Naoki Tanaka , Takeshi Fukuda , Takashi Tsuji , Riki Goto
发明人: Takeshi Kuribayashi , Hideki Kubota , Naoki Tanaka , Takeshi Fukuda , Takashi Tsuji , Riki Goto
IPC分类号: A61K31/505 , A61K31/40 , C07D239/02
CPC分类号: C07D401/06 , C07D401/14
摘要: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group α: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.
摘要翻译: 本发明提供了促进促红细胞生成素生成的化合物。 本发明提供由式(1)表示的化合物:[其中,R1:式(1A):[其中,R4和R5:H,卤素或烷基; R6:H,卤素,烷基等; R7:可取代的羟烷基,可取代的羟基卤代烷基,可取代的烷氧基烷基等; 取代基组α:氧代,羟基,氨基等; 环Q1:单环杂环基; 环Q2:单环烃环基或单环杂环基; 环Q3:单环烃环基或单环杂环基; X:单键,亚甲基,亚乙基等); R2:烷基或甲硫基; 和R 3:H或甲基]等。
-
公开(公告)号:US20120220609A1
公开(公告)日:2012-08-30
申请号:US13503340
申请日:2010-10-20
申请人: Takeshi Kuribayashi , Hideki Kubota , Naoki Tanaka , Takeshi Fukuda , Takashi Tsuji , Riki Goto
发明人: Takeshi Kuribayashi , Hideki Kubota , Naoki Tanaka , Takeshi Fukuda , Takashi Tsuji , Riki Goto
IPC分类号: A61K31/506 , C07D401/14 , A61P7/06 , C07D401/06
CPC分类号: C07D401/06 , C07D401/14
摘要: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group α: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.
摘要翻译: 本发明提供了促进促红细胞生成素生成的化合物。 本发明提供由式(1)表示的化合物:[其中,R1:式(1A):[其中,R4和R5:H,卤素或烷基; R6:H,卤素,烷基等; R7:可取代的羟烷基,可取代的羟基卤代烷基,可取代的烷氧基烷基等; 取代基组α:氧代,羟基,氨基等; 环Q1:单环杂环基; 环Q2:单环烃环基或单环杂环基; 环Q3:单环烃环基或单环杂环基; X:单键,亚甲基,亚乙基等); R2:烷基或甲硫基; 和R 3:H或甲基]等。
-
公开(公告)号:US20110112103A1
公开(公告)日:2011-05-12
申请号:US12988947
申请日:2009-04-21
申请人: Takeshi Kuribayashi , Hideki Kubota , Takeshi Fukuda , Rieko Takano , Takashi Tsuji , Koji Sasaki , Naoki Tanaka
发明人: Takeshi Kuribayashi , Hideki Kubota , Takeshi Fukuda , Rieko Takano , Takashi Tsuji , Koji Sasaki , Naoki Tanaka
IPC分类号: A61K31/513 , C07D401/06 , C07D401/14 , C07D409/14 , C07D417/14 , C07D413/14 , C07D403/14 , C07D405/14 , C07D401/10 , C07D405/06 , A61P7/06
CPC分类号: C07D239/34 , C07D239/52 , C07D239/56 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/14 , C07D451/02 , C07D471/04
摘要: The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R1 represents a group —X-Q1, X-Q1-Y-Q2 or X-Q1-Y-Q2-Z-Q3, X represents a single bond, —CH2— or the like, Q1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH2—, or the like, Q2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR11R12— or the like, R11 and R12 each independently represents a hydrogen atom, a halogen atom or the like, Q3 represents a phenyl group which may have substituent(s), a C3-C7 cycloalkyl group which may have substituent(s), a C3-C7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R2 represents a C1-C3 alkyl group or the like, and R3 represents a hydrogen atom or a methyl group].
摘要翻译: 本发明提供促进促红细胞生成素生成的化合物。 提供了由以下通式(1)表示的化合物或其药理学上可接受的盐:[其中,R1表示-X-Q1,X-Q1-Y-Q2或X-Q1-Y-Q2-Z-Q3, X表示单键,-CH 2 - 等,Q 1表示可具有取代基的单环或双环杂环基,Y表示单键,-CH 2 - 等,Q 2表示单环或双环烃 可以具有取代基的环基或可以具有取代基的单环或双环杂环基,Z表示单键,-CR 11 R 12 - 等,R 11和R 12各自独立地表示氢原子,卤素原子 Q3表示可具有取代基的苯基,可具有取代基的C3-C7环烷基,可具有取代基的C3-C7环烯基或单环或双环杂环 可以具有取代基的基团,R2表示C1-C3烷基等,R3表示 呈现氢原子或甲基]。
-
公开(公告)号:US20060241302A1
公开(公告)日:2006-10-26
申请号:US10561838
申请日:2004-06-29
申请人: Hideki Kubota , Takanori Yasukouchi , Satoru Miyauchi , Kayoko Motoki , Masanori Saito , Hitoshi Iimori
发明人: Hideki Kubota , Takanori Yasukouchi , Satoru Miyauchi , Kayoko Motoki , Masanori Saito , Hitoshi Iimori
IPC分类号: C07D403/02 , C07D401/02 , C07D213/02
CPC分类号: C07D213/30 , C07C317/14 , C07C2601/14
摘要: Provided is a compound capable of inhibiting production or secretion of β amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents —S—, —SO— or —SO2—); an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.
摘要翻译: 提供能够抑制β淀粉样蛋白的产生或分泌的化合物。 由下式(1)表示的化合物:其中R 1表示可以具有取代基的杂环基,R 2表示可以具有 可以具有取代基的取代基或杂环基,R 3表示可以具有取代基的环状烃基或可以具有取代基的杂环基,R 4, 表示氢原子或C 1-6烷基,X表示-S - , - SO-或-SO 2 - )。 其N-氧化物或S-氧化物; 其盐; 或其溶剂合物; 和含有它们中任何一种的药物。
-
公开(公告)号:US08314240B2
公开(公告)日:2012-11-20
申请号:US13000677
申请日:2009-06-22
申请人: Hideki Kubota , Issei Tsukamoto , Kazunori Kamijo , Koji Kato , Yuta Fukuda , Hidenori Azami
发明人: Hideki Kubota , Issei Tsukamoto , Kazunori Kamijo , Koji Kato , Yuta Fukuda , Hidenori Azami
IPC分类号: A61K31/44 , C07D213/62
CPC分类号: C07C311/21 , A61K31/341 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , C07C2602/08 , C07D213/71 , C07D213/80 , C07D277/20 , C07D277/36 , C07D277/56 , C07D307/64 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
摘要: [Object] A compound which is useful as an EP1 receptor antagonist is provided.[Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
摘要翻译: 提供了可用作EP1受体拮抗剂的化合物。 [解决方案]本发明人研究了EP1受体拮抗剂,并证实了具有磺酰胺结构的化合物,其中磺酰胺结构的氮原子被2-氟丙基取代,3-氟-2-甲基丙基或 具有有效的EP1受体拮抗作用,从而完成本发明。 本发明的磺酰胺化合物具有有效的EP1受体拮抗作用,可用作预防和/或治疗下尿路症状等的药剂。
-
公开(公告)号:US20110319385A1
公开(公告)日:2011-12-29
申请号:US13254368
申请日:2010-03-04
申请人: Hiroyuki Kaizawa , Mari Sugita , Hidenori Azami , Ryushi Seo , Takaho Nomura , Satoshi Yamamoto , Hirofumi Yamamoto , Kazuyuki Tsuchiya , Hideki Kubota , Kazunori Kamijo
发明人: Hiroyuki Kaizawa , Mari Sugita , Hidenori Azami , Ryushi Seo , Takaho Nomura , Satoshi Yamamoto , Hirofumi Yamamoto , Kazuyuki Tsuchiya , Hideki Kubota , Kazunori Kamijo
IPC分类号: A61K31/4985 , C07D413/14 , A61P13/00 , A61K31/5377 , A61K31/55 , C07D487/04 , C07D403/14
CPC分类号: C07D498/04 , C07D487/04 , C07D491/107 , C07D519/00
摘要: [Problem]Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.[Means for Solution]The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.
摘要翻译: [问题]提供具有PDE9抑制作用并可用作治疗和/或预防储存功能障碍,排尿功能障碍和膀胱/尿道疾病的药剂的活性成分的化合物等。 [解决方案]本发明人已经研究了具有PDE9抑制作用并可用作治疗和/或预防储存功能障碍,排尿功能障碍和膀胱/尿道疾病等的活性成分的化合物 ,因此已经发现咪唑并喹喔啉化合物或三唑并喹喔啉化合物具有抑制PDE9的作用,从而完成了本发明。 本发明的咪唑并喹喔啉化合物或三唑并喹喔啉化合物具有PDE9抑制作用,可用作预防和/或治疗储存功能障碍,排尿功能障碍和膀胱/尿道疾病等的药剂。
-
公开(公告)号:US07375222B2
公开(公告)日:2008-05-20
申请号:US10503494
申请日:2003-02-03
申请人: Hideki Kubota , Takeshi Suzuki , Masanori Miura , Eiichi Nakai , Kiyoshi Yahiro , Akira Miyake , Shinobu Mochizuki , Kazuhiro Nakatou
发明人: Hideki Kubota , Takeshi Suzuki , Masanori Miura , Eiichi Nakai , Kiyoshi Yahiro , Akira Miyake , Shinobu Mochizuki , Kazuhiro Nakatou
IPC分类号: C07D251/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/53 , A61P25/28
CPC分类号: C07D471/04 , A61K31/53 , C07D251/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D453/02 , C07D491/04
摘要: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient.It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned.Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder.Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.
摘要翻译: 本发明涉及使用BEC 1钾通道抑制剂作为活性成分的抗痴呆药。 证明BEC 1钾通道抑制剂具有改善学习障碍的作用,可用作预防或治疗BEC 1钾通道所涉及的疾病,优选痴呆症。 说明性地,通过体内试验证实BEC 1钾通道抑制剂具有改善学习障碍的作用。 此外,发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾通道抑制作用。
-
公开(公告)号:USD551167S1
公开(公告)日:2007-09-18
申请号:US29230178
申请日:2005-05-18
申请人: Hideki Kubota , Tsuyoshi Konishi
设计人: Hideki Kubota , Tsuyoshi Konishi
-
公开(公告)号:US20060194844A1
公开(公告)日:2006-08-31
申请号:US10564520
申请日:2004-07-15
申请人: Keizo Sugasawa , Yuji Koga , Kazuyoshi Obitsu , Takao Okuda , Koichiro Harada , Hideki Kubota , Fukushi Hirayama , Masaki Abe , Ken-ichi Suzuki
发明人: Keizo Sugasawa , Yuji Koga , Kazuyoshi Obitsu , Takao Okuda , Koichiro Harada , Hideki Kubota , Fukushi Hirayama , Masaki Abe , Ken-ichi Suzuki
IPC分类号: C07D417/02 , A61K31/4439 , A61K31/426
CPC分类号: C07D417/14 , C07D417/04
摘要: 2-Acylaminothiazole derivatives or salts thereof which have a platelet increasing activity based on an excellent human c-mpl-Ba/F3 cell growth function and a function of accelerating formation of megakaryocytic colonies and which are useful for treating thrombocytopenia are provided.
摘要翻译: 提供了基于优异的人c-mpl-Ba / F3细胞生长功能具有血小板增加活性的2-酰基氨基噻唑衍生物或其盐,并且具有促进巨核细胞集落形成并且可用于治疗血小板减少症的功能。
-
公开(公告)号:US20050239780A1
公开(公告)日:2005-10-27
申请号:US10514636
申请日:2003-05-29
申请人: Akira Suga , Hideki Kubota , Masanori Miura , Daisuke Sasuga , Hiroshi Moritani
发明人: Akira Suga , Hideki Kubota , Masanori Miura , Daisuke Sasuga , Hiroshi Moritani
IPC分类号: A61P1/18 , A61P3/04 , A61P3/06 , A61P9/10 , A61P43/00 , C07D405/08 , C07D405/14 , C07D471/04 , C07D519/00 , A61K31/5377 , A61K31/496 , C07D471/02
CPC分类号: C07D405/08 , C07D405/14 , C07D471/04
摘要: The invention has succeeded in settling the aforementioned problems by finding that a novel tetrahydropyran derivative has excellent apo B-related lipoprotein secretion-inhibiting activity.
摘要翻译: 本发明通过发现新型四氢吡喃衍生物具有优异的载脂蛋白B相关脂蛋白分泌抑制活性而成功地解决了上述问题。
-
-
-
-
-
-
-
-
-